| . | Pooled somapacitan groups . | . | . | . | Daily GH 0.034 mg/kg/da . | . | . | . |
|---|---|---|---|---|---|---|---|---|
| . | N . | (%) . | E . | R . | N . | (%) . | E . | R . |
| Patients exposed | 45 | 14 | ||||||
| All events | 32 | 71.1 | 189 | 237.7 | 10 | 71.4 | 50 | 224.9 |
| Mild events | 30 | 66.7 | 170 | 213.8 | 9 | 64.3 | 44 | 197.9 |
| Moderate events | 11 | 24.4 | 19 | 23.9 | 2 | 14.3 | 5 | 22.5 |
| Severe events | 0 | - | - | - | 1 | 7.1 | 1 | 4.5 |
| Probably related | 4 | 8.9 | 7 | 8.8 | 1 | 7.1 | 1 | 4.5 |
| Possibly related | 4 | 8.9 | 5 | 6.3 | 2 | 14.3 | 5 | 22.5 |
| Unlikely related | 32 | 71.1 | 177 | 222.6 | 10 | 71.4 | 44 | 197.9 |
| . | Pooled somapacitan groups . | . | . | . | Daily GH 0.034 mg/kg/da . | . | . | . |
|---|---|---|---|---|---|---|---|---|
| . | N . | (%) . | E . | R . | N . | (%) . | E . | R . |
| Patients exposed | 45 | 14 | ||||||
| All events | 32 | 71.1 | 189 | 237.7 | 10 | 71.4 | 50 | 224.9 |
| Mild events | 30 | 66.7 | 170 | 213.8 | 9 | 64.3 | 44 | 197.9 |
| Moderate events | 11 | 24.4 | 19 | 23.9 | 2 | 14.3 | 5 | 22.5 |
| Severe events | 0 | - | - | - | 1 | 7.1 | 1 | 4.5 |
| Probably related | 4 | 8.9 | 7 | 8.8 | 1 | 7.1 | 1 | 4.5 |
| Possibly related | 4 | 8.9 | 5 | 6.3 | 2 | 14.3 | 5 | 22.5 |
| Unlikely related | 32 | 71.1 | 177 | 222.6 | 10 | 71.4 | 44 | 197.9 |
Abbreviations: %, percentage of patients; E, number of events; R, event rate per 100 patient-years at risk.
aEquivalent to 0.238 mg/kg/wk.
| . | Pooled somapacitan groups . | . | . | . | Daily GH 0.034 mg/kg/da . | . | . | . |
|---|---|---|---|---|---|---|---|---|
| . | N . | (%) . | E . | R . | N . | (%) . | E . | R . |
| Patients exposed | 45 | 14 | ||||||
| All events | 32 | 71.1 | 189 | 237.7 | 10 | 71.4 | 50 | 224.9 |
| Mild events | 30 | 66.7 | 170 | 213.8 | 9 | 64.3 | 44 | 197.9 |
| Moderate events | 11 | 24.4 | 19 | 23.9 | 2 | 14.3 | 5 | 22.5 |
| Severe events | 0 | - | - | - | 1 | 7.1 | 1 | 4.5 |
| Probably related | 4 | 8.9 | 7 | 8.8 | 1 | 7.1 | 1 | 4.5 |
| Possibly related | 4 | 8.9 | 5 | 6.3 | 2 | 14.3 | 5 | 22.5 |
| Unlikely related | 32 | 71.1 | 177 | 222.6 | 10 | 71.4 | 44 | 197.9 |
| . | Pooled somapacitan groups . | . | . | . | Daily GH 0.034 mg/kg/da . | . | . | . |
|---|---|---|---|---|---|---|---|---|
| . | N . | (%) . | E . | R . | N . | (%) . | E . | R . |
| Patients exposed | 45 | 14 | ||||||
| All events | 32 | 71.1 | 189 | 237.7 | 10 | 71.4 | 50 | 224.9 |
| Mild events | 30 | 66.7 | 170 | 213.8 | 9 | 64.3 | 44 | 197.9 |
| Moderate events | 11 | 24.4 | 19 | 23.9 | 2 | 14.3 | 5 | 22.5 |
| Severe events | 0 | - | - | - | 1 | 7.1 | 1 | 4.5 |
| Probably related | 4 | 8.9 | 7 | 8.8 | 1 | 7.1 | 1 | 4.5 |
| Possibly related | 4 | 8.9 | 5 | 6.3 | 2 | 14.3 | 5 | 22.5 |
| Unlikely related | 32 | 71.1 | 177 | 222.6 | 10 | 71.4 | 44 | 197.9 |
Abbreviations: %, percentage of patients; E, number of events; R, event rate per 100 patient-years at risk.
aEquivalent to 0.238 mg/kg/wk.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
